TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics to $55 from $60 and keeps an Outperform rating on the shares. The firm said despite the 3Q beat and raise, they view the 3Q as mixed, with continued very strong Spatial ramp and upside juxtaposed against weak Single Cell.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on TXG: